COMP <GO>
ABVC vs CRVO // FREE CASH FLOW YIELD
ABVC BioPharma Inc. (NASDAQ) VS. CervoMed Inc. (NASDAQ) • 15-METRIC TALLY: ABVC 2
— CRVO 1
■ METRIC PARITY
LAST: $1.04 (-4.59%) • MKT CAP: $27.8M
fcf-yield
-10.76%
LAST: $1.75 (-20.81%) • MKT CAP: $26.5M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABVC VS. CRVO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABVC | CRVO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -10.76% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -58.90% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 2/9 | -1.00 | CRVO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.3 | 24.1 | +24.19 | ABVC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $27.8M | $26.5M | $1.3M | ABVC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABVC REV | CRVO REV | ABVC GROSS % | CRVO GROSS % | ABVC FCF | CRVO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $4.0M | — | — | -$3.0M | -$23.4M |
| FY 2024 | $509.6K | $9.7M | 98.0% | — | -$1.8M | -$16.5M |
| FY 2023 | $152.4K | $7.1M | — | — | -$4.2M | -$7.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABVC // BETA —
CRVO // BETA —